--- title: "Hemab ApS – CVR 40837590, financials and ownership" description: "Hemab ApS (CVR 40837590): Hemab develops targeted therapies for serious bleeding disorders, with a focus on conditions underserved by existing treatment options." canonical_url: "https://datapublica.dk/en/companies/40837590-hemab-aps" locale: "en" route_type: "company_overview" robots: "index,follow" --- # Hemab ApS Hemab ApS \(CVR 40837590\): Hemab develops targeted therapies for serious bleeding disorders, with a focus on conditions underserved by existing treatment options. CVR number: 40837590 ## Company details - **CVR number:** 40837590 - **Status:** Aktiv - **Address:** Nordre Fasanvej 215, 2000, Frederiksberg - **Legal form:** Anpartsselskab \(ApS\) - **Founded:** Sep 27, 2019 - **Employees / FTEs:** 46 / 45 - **Production units:** 1 - **Website:** https://www.hemab.com/ - **Instagram:** @hemab\_therapeutics - **LinkedIn:** hemabaps - **LEI:** 63670015L6E0YUANC846 ## Description Hemab develops targeted therapies for serious bleeding disorders, with a focus on conditions underserved by existing treatment options. Hemab develops therapies for blood coagulation disorders, including researching treatment approaches intended to prevent bleeding and improve disease management. ### Company's own description on virk.dk Hemab is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Based in Denmark and the United States, Hemab's mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause significant life-long burden to patients. Hemab's assets address critical gaps in the treatment of coagulation disorders. ### Products & services Therapies for blood coagulation disorders • Therapeutic product candidates and clinical research programs • Natural history studies ### Industries Biotechnology • Therapeutics development • Blood coagulation disorders ### Customer types Patients with serious bleeding disorders • Healthcare professionals • Potential clinical investigators ## Analysis by AI ✨ Hemab expanded its workforce from 20 employees in January 2025 to 46 in July 2026; full-time equivalents rose from 19 to 45 over the same periods. On 23 October 2025, the company increased its nominal capital by DKK 512,991 to DKK 1,247,405 through a cash capital increase. On 30 March 2026, [Hemab Therapeutics Holdings, Inc.](https://datapublica.dk/en/participants/pid_owner_enhed_4010760327-hemab-therapeutics-holdings-inc) was registered as the direct legal owner with 100%; its registered country is the United States. The previous investors were deregistered on the same date. Hemab was founded under the name Ebumab Hemophilia ApS and changed its name to Hemab ApS on 22 June 2020. AI-generated texts are based on registered information, which may be delayed or incomplete. Errors may occur. ## Activities and industry - Fremstilling af farmaceutiske præparater - 212000 — Fremstilling af farmaceutiske præparater ## Latest financial period - **Reporting period:** 2025 - **Currency:** USD - **Profit after tax:** -61,353,000 - **Assets:** 195,363,000 - **Equity:** 183,422,000 ## People | Person | Roles | Titles | | --- | --- | --- | | [Benny Sørensen](https://datapublica.dk/en/people/pid_entity_4000422096-benny-s-rensen) | Board • Management | BESTYRELSESMEDLEM • ADM. DIR. | | [Mads Nikolaj Behrndt-Eriksen](https://datapublica.dk/en/people/pid_entity_4008401087-mads-nikolaj-behrndt-eriksen) | Management | DIREKTØR | ## Auditor | Audit firm | Auditor | Role | From | | --- | --- | --- | --- | | EY | Christian Schwenn Johansen | State Authorised Public Accountant | Jun 30, 2026 | | — | Mads Obel Knøsgaard | State Authorised Public Accountant | Jun 30, 2026 | ## Legal owners ### Current | Owner | Ownership | Voting rights | From | | --- | --- | --- | --- | | OwnerHemab Therapeutics Holdings, Inc. | Ownership100 % | Voting rights100 % | FromMar 30, 2026 | ### Previous | Owner | Ownership | Voting rights | From | To | | --- | --- | --- | --- | --- | | OwnerNovo Holdings A/S | Ownership15–19.99 % | Voting rights15 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerAI DEN-MAB LLC | Ownership10–14.99 % | Voting rights10 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerRA Capital Healthcare Fund, L.P. | Ownership10–14.99 % | Voting rights10 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerDEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. | Ownership5–9.99 % | Voting rights5 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerHealthCap VIII L.P. | Ownership5–9.99 % | Voting rights5 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerSMALLCAP World Fund, Inc. | Ownership5–9.99 % | Voting rights5 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerSofinnova Crossover II S.L.P. | Ownership5–9.99 % | Voting rights5 % | FromOct 23, 2025 | ToMar 30, 2026 | | OwnerAVORO VENTURES FUND L.P. | Ownership5–9.99 % | Voting rights5 % | FromFeb 15, 2023 | ToOct 23, 2025 | | OwnerEbumab Holding ApS | Ownership5–9.99 % | Voting rights5 % | FromFeb 15, 2023 | ToOct 23, 2025 | | OwnerRA Capital Nexus Fund II, L.P. | Ownership5–9.99 % | Voting rights5 % | FromFeb 15, 2023 | ToOct 23, 2025 | | OwnerNovo Holdings A/S | Ownership20–24.99 % | Voting rights20 % | FromFeb 15, 2023 | ToOct 22, 2025 | | OwnerAI DEN-MAB LLC | Ownership15–19.99 % | Voting rights15 % | FromFeb 15, 2023 | ToOct 22, 2025 | | OwnerHealthCap VIII L.P. | Ownership10–14.99 % | Voting rights10 % | FromFeb 15, 2023 | ToOct 22, 2025 | | OwnerRA Capital Healthcare Fund, L.P. | Ownership10–14.99 % | Voting rights10 % | FromFeb 15, 2023 | ToOct 22, 2025 | | OwnerDEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. | Ownership5–9.99 % | Voting rights5 % | FromFeb 15, 2023 | ToOct 22, 2025 | | OwnerEbumab Holding ApS | Ownership10–14.99 % | Voting rights10 % | FromJan 14, 2023 | ToFeb 14, 2023 | | OwnerHealthCap VIII L.P. | Ownership20–24.99 % | Voting rights20 % | FromDec 20, 2022 | ToFeb 14, 2023 | | OwnerRA Capital Healthcare Fund, L.P. | Ownership20–24.99 % | Voting rights20 % | FromDec 20, 2022 | ToFeb 14, 2023 | | OwnerNovo Holdings A/S | Ownership25–33.32 % | Voting rights25 % | FromMay 4, 2022 | ToFeb 14, 2023 | | OwnerRA Capital Nexus Fund II, L.P. | Ownership5–9.99 % | Voting rights5 % | FromJul 22, 2021 | ToFeb 14, 2023 | | OwnerEbumab Holding ApS | Ownership15–19.99 % | Voting rights15 % | FromDec 20, 2022 | ToJan 13, 2023 | | OwnerEbumab Holding ApS | Ownership20–24.99 % | Voting rights20 % | FromMay 4, 2022 | ToDec 19, 2022 | | OwnerHealthCap VIII L.P. | Ownership15–19.99 % | Voting rights15 % | FromMay 4, 2022 | ToDec 19, 2022 | | OwnerRA Capital Healthcare Fund, L.P. | Ownership15–19.99 % | Voting rights15 % | FromMay 4, 2022 | ToDec 19, 2022 | | OwnerNovo Holdings A/S | Ownership33.33–49.99 % | Voting rights33.33 % | FromJul 22, 2021 | ToMay 3, 2022 | | OwnerEbumab Holding ApS | Ownership25–33.32 % | Voting rights25 % | FromJul 22, 2021 | ToMay 3, 2022 | | OwnerHealthCap VIII L.P. | Ownership10–14.99 % | Voting rights10 % | FromJul 22, 2021 | ToMay 3, 2022 | | OwnerRA Capital Healthcare Fund, L.P. | Ownership10–14.99 % | Voting rights10 % | FromJul 22, 2021 | ToMay 3, 2022 | | OwnerEbumab Holding ApS | Ownership50–66.66 % | Voting rights50 % | FromNov 20, 2020 | ToJul 21, 2021 | | OwnerNovo Holdings A/S | Ownership33.33–49.99 % | Voting rights33.33 % | FromNov 20, 2020 | ToJul 21, 2021 | | OwnerGV1 Holding ApS | Ownership5–9.99 % | Voting rights5 % | FromJun 22, 2020 | ToNov 20, 2020 | | OwnerEbumab Holding ApS | Ownership90–99.99 % | Voting rights90 % | FromJun 22, 2020 | ToNov 19, 2020 | | OwnerEbumab Holding ApS | Ownership100 % | Voting rights100 % | FromSep 27, 2019 | ToJun 21, 2020 | ## Ultimate owners [View ownership diagram](https://datapublica.dk/en/companies/40837590-hemab-aps/portfolio) | Name | Ownership through | Calculated ownership | | --- | --- | --- | | Hemab Therapeutics Holdings, Inc. | Direct | 100 % | ## Company pages - [Overview](https://datapublica.dk/en/companies/40837590-hemab-aps) - [Financial report](https://datapublica.dk/en/companies/40837590-hemab-aps/financials) - [Risk](https://datapublica.dk/en/companies/40837590-hemab-aps/risk) - [Timeline](https://datapublica.dk/en/companies/40837590-hemab-aps/timeline) - [Ownership and relations](https://datapublica.dk/en/companies/40837590-hemab-aps/portfolio) - [Production units](https://datapublica.dk/en/companies/40837590-hemab-aps/production-units) - [Gazelle](https://datapublica.dk/en/companies/40837590-hemab-aps/gazelle) - [Investments](https://datapublica.dk/en/companies/40837590-hemab-aps/investments) - [Company website](https://www.hemab.com/) ## Official sources - [Official CVR record on Virk](https://datacvr.virk.dk/enhed/virksomhed/40837590) - [Official LEI record at GLEIF](https://www.gleif.org/)